Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia / Christoph U. Correll en The Journal of Clinical Psychiatry, Año 2019 - Vol. 80 - No. 2 (Marzo - Abril)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No. 2 (Marzo - Abril) . - pp. 49-55 Título : Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia : A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial Tipo de documento: texto impreso Autores: Christoph U. Correll, Autor ; Steven G. Potkin, Autor ; Yan Zhong, Autor Fecha de publicación: 2019 Artículo en la página: pp. 49-55 Idioma : Inglés (eng) Palabras clave: Esquizofrenia, Cariprazina - remisión a largo plazo. Resumen: Long-term remission is an important treatment goal in schizophrenia. Cariprazine, a dopamine D3/D2 receptor and serotonin 5-HT1A receptor partial agonist, is approved in the United States and Europe to treat adults with schizophrenia. Link: ./index.php?lvl=notice_display&id=20617 [artículo] Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia : A Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Trial [texto impreso] / Christoph U. Correll, Autor ; Steven G. Potkin, Autor ; Yan Zhong, Autor . - 2019 . - pp. 49-55. Idioma : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2019 - Vol. 80 - No. 2 (Marzo - Abril) . - pp. 49-55 Palabras clave: Esquizofrenia, Cariprazina - remisión a largo plazo. Resumen: Long-term remission is an important treatment goal in schizophrenia. Cariprazine, a dopamine D3/D2 receptor and serotonin 5-HT1A receptor partial agonist, is approved in the United States and Europe to treat adults with schizophrenia. Link: ./index.php?lvl=notice_display&id=20617

---

1 (1 - 1 / 1)